Cargando…

Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

BACKGROUND: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. OBJECTIVE: This study aimed to examine QoL,...

Descripción completa

Detalles Bibliográficos
Autores principales: Eitel, Tamara, Zeiner, Kim Nikola, Assmus, Katharina, Ackermann, Hanns, Zoeller, Nadja, Meissner, Markus, Kaufmann, Roland, Kippenberger, Stefan, Valesky, Eva Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085710/
https://www.ncbi.nlm.nih.gov/pubmed/33995819
http://dx.doi.org/10.1016/j.waojou.2021.100536
_version_ 1783686401720582144
author Eitel, Tamara
Zeiner, Kim Nikola
Assmus, Katharina
Ackermann, Hanns
Zoeller, Nadja
Meissner, Markus
Kaufmann, Roland
Kippenberger, Stefan
Valesky, Eva Maria
author_facet Eitel, Tamara
Zeiner, Kim Nikola
Assmus, Katharina
Ackermann, Hanns
Zoeller, Nadja
Meissner, Markus
Kaufmann, Roland
Kippenberger, Stefan
Valesky, Eva Maria
author_sort Eitel, Tamara
collection PubMed
description BACKGROUND: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. OBJECTIVE: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). METHODS: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36). To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n = 45), (B) VIT before carrying out SC (n = 73), and (C) therapy-naïve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. RESULTS: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients’ age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. CONCLUSION: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients’ QoL.
format Online
Article
Text
id pubmed-8085710
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher World Allergy Organization
record_format MEDLINE/PubMed
spelling pubmed-80857102021-05-13 Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy Eitel, Tamara Zeiner, Kim Nikola Assmus, Katharina Ackermann, Hanns Zoeller, Nadja Meissner, Markus Kaufmann, Roland Kippenberger, Stefan Valesky, Eva Maria World Allergy Organ J Article BACKGROUND: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. OBJECTIVE: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). METHODS: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36). To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n = 45), (B) VIT before carrying out SC (n = 73), and (C) therapy-naïve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. RESULTS: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients’ age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. CONCLUSION: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients’ QoL. World Allergy Organization 2021-04-21 /pmc/articles/PMC8085710/ /pubmed/33995819 http://dx.doi.org/10.1016/j.waojou.2021.100536 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eitel, Tamara
Zeiner, Kim Nikola
Assmus, Katharina
Ackermann, Hanns
Zoeller, Nadja
Meissner, Markus
Kaufmann, Roland
Kippenberger, Stefan
Valesky, Eva Maria
Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
title Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
title_full Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
title_fullStr Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
title_full_unstemmed Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
title_short Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
title_sort impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085710/
https://www.ncbi.nlm.nih.gov/pubmed/33995819
http://dx.doi.org/10.1016/j.waojou.2021.100536
work_keys_str_mv AT eiteltamara impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT zeinerkimnikola impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT assmuskatharina impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT ackermannhanns impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT zoellernadja impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT meissnermarkus impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT kaufmannroland impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT kippenbergerstefan impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy
AT valeskyevamaria impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy